Your Search Returned 63 tagged news reports
Anybody who has ever seen a drug advertisement or talked over the pros and cons of a medicine with a doctor can be forgiven for being confused. Sorting out the risks and benefits of taking a medicine can be complicated even for professionals. This
If you rely on sleeping pills for a good night's sleep, take note: a recent study found that those who took sleeping aids like Ambien and Lunesta had a higher risk of dying sooner or developing cancer. While the jury's still out on whether the study
Along with campaigns to dissuade older patients from having so many screening tests (like mammograms , Pap smears and colonoscopies ) and potentially harmful procedures, researchers now are trying to help them kick certain prescription drugs.
A year and a half ago, the FDA announced that it would require the makers of sleep drugs, including those that contain the ingredient zolpidem (used in popular brands, such as Ambien), to reduce the recommended dose for women. The decision was
The Food and Drug Administration warned that anyone prescribed the sleeping medication Lunesta might want to start their dosages at half strength, to about 1 milligram. The federal agency ordered the manufacturer, Sunovion Pharmaceuticals, to change
Patients starting on the sleep drug eszopiclone (Lunesta) should take no more than 1 mg at bedtime one-third the current label-recommended dose because of the risk of next-day impairment.
Federal health officials are lowering the starting dose of the popular sleeping aid drug Lunesta, due to risks of morning drowsiness that can impair driving ability and lead to injury. The Food and Drug Administration said Thursday it is taking
Federal health officials say the maker of Lunesta must lower the starting dose of its sleeping aid drug due to risks of morning drowsiness, which can interfere with driving ability and lead to injury. Voter turnout for West Virginia's primary
People who take prescription drugs for anxiety or to induce sleep are significantly more prone to early death than others, suggests a new study recently published in the British Medical Journal (BMJ). A team of researchers from the U.K. found that
The approval is for the 1 mg, 2 mg and 3 mg tablets," Glenmark said in the statement. Glenmark shares quoted at Rs 582.40 on the BSE, up 0.18 per cent. ©